Corporate Magazine 2012 - Boehringer Ingelheim

usiness year 2012 key aspects 2012Successful long-term, sustainable development of the company, allied with stableearnings and sound finances, is and will remain the basis of our independence andis central to the strategic direction of the Boehringer Ingelheim group of companies.Besides independence, the paramount goal is our most important endeavour tomake in equal measure available a high level of medical progress to patients andphysicians treating them by researching innovative medicines, especially in indicationswith urgent medical need.Growth maintainedIn 2012, Boehringer Ingelheim was able to build on its successful, above-marketgrowth from the previous year and achieved a growth rate of + 11.5%. We therebyjudge 2012 to be a successful year. Exchange rate developments in the currencymarkets, and the the currency effect associated with them, furthermore had anadditional EUR 664 million positive impact of the company‘s growth (currencyadjustedour growth was + 6.6%).Both our new products, such as the anticoagulant pradaxa® and the diabetes medicationtrajenta®, as well as established products, such as the respiratory medicinesspiriva® and combivent®, were the main growth drivers – all products from ourown research.In external comparisons of pharmaceutical companies, Boehringer Ingelheim is,according to the data from independent market research companies, again one ofthe fastest growing companies.Stable earnings and financial position in a difficult marketBoehringer Ingelheim made an operating profit of EUR 1,853 million. This correspondsto an operating margin of 12.6%.Key aspects 201211